ライフサイエンスコーパス: asthmatic response

1 13 are thought to be central to the allergic asthmatic response.

2 a key role in the activation of the allergic asthmatic response.

3 ory T cells into the BAL during the allergic asthmatic response.

4 cumulative component of the allergen-induced asthmatic response.

5 diator that is released in airways during an asthmatic response.

6 returned to baseline levels during the late asthmatic response.

7 e mechanism by which PGE(2) blocks the early asthmatic response.

8 nt effect on the allergen-induced dual-phase asthmatic response.

9 gnificantly reduce either the early- or late-asthmatic response.

10 s no effect on the fall in FEV1 during early asthmatic response.

11 after allergen challenge for early and late asthmatic responses.

12 measures of allergen-induced early and late asthmatic responses.

13 clinically attractive therapy for allergic, asthmatic responses.

14 ibutes to the development of severe allergic asthmatic responses.

15 nt for diminishing allergic and IgE-mediated asthmatic responses.

16 significantly attenuated both late and early asthmatic responses after allergen provocation in patien

17 lia and who also had biphasic early and late asthmatic responses after laboratory-based allergen prov

18 he role of eosinophils in mediating the late asthmatic response and causing airway hyper-responsivene

19 to increase during the immediate Ag-induced asthmatic response and continued to increase over 2-fold

20 s study introduce a novel participant in the asthmatic response and indicate that factor Xa functions

21 erged as a major contributor to allergic and asthmatic responses, and as such it represents an attrac

22 lammation in the lungs, inhibit allergic and asthmatic responses, and contribute to tolerance to inha

23 Enhanced asthmatic response as a result of ovalbumin sensitizatio

24 The primary end point was the late asthmatic response as quantified by the change in the ar

25 The primary end point was the late asthmatic response, as measured 3 to 7 hours after the a

26 whether selective inhibition of COX-2 makes asthmatic responses better or worse.

27 attenuated the fall in FEV1 during the late asthmatic response (both doses led to an 8.7% fall) vers

28 Inhaled prostaglandin (PG) E2 might inhibit asthmatic responses, but the mechanisms involved remain

29 t rich in IL-4, these CD8(+) T cells mediate asthmatic responses, but the mechanisms regulating the c

30 fter 28 days, SB010 attenuated the mean late asthmatic response by 34%, as compared with the baseline

31 Inhibition of the late asthmatic response by SB010 was associated with attenuat

32 We hypothesized that a pre-existing Th2/asthmatic response can promote Th2 responses to newly en

33 tically significant attenuation of the early asthmatic response (EAR) by GSK2190915; treatment differ

34 ist (LABA) vilanterol (VI) on early and late asthmatic responses (EAR/LAR) and airway hyper-responsiv

35 The enhanced severity of the asthmatic response from disruption of the Nrf2 pathway w

36 ponse, whereas nitrosylation during the late asthmatic response generates SNO, safe reservoirs for re

37 specific chemokine receptors during allergic asthmatic responses has been relatively undefined.

38 combinant PAF-AH (rPAF-AH) on the dual phase asthmatic response in atopic subjects with mild asthma.

39 used to determine effects of factor X on the asthmatic response in mice.

40 and placebo, for 7 days, on allergen-induced asthmatic responses in 18 non-smoking and 17 smoking ato

41 ach allergen (CRA), an allergen that induces asthmatic responses in both humans and mice, to further

42 Lipoxin A4 (LXA4) signaling blocks asthmatic responses in human and experimental model syst

43 Allergic asthmatic responses in the airway are associated with ai

44 In allergic asthmatic responses increased lung homing of HPCs may be

45 btained at 4 h (n = 7), the time of the late asthmatic response (LAR) (n = 5), or 24 h (n = 4) after

46 Primary efficacy outcome was late asthmatic response (LAR) at Week 13, defined as area und

47 stically significant attenuation of the late asthmatic response (LAR) by GSK2190915; the treatment di

48 The late asthmatic response (LAR) was suppressed by FP in smokers

49 To identify predictors of the late asthmatic response (LAR), we reviewed data from 60 asthm

50 rgen would seem to dictate the nature of the asthmatic response, little is known regarding how tolera

51 t of monoclonal antibody to IL-5 on the late asthmatic response or on airway hyper-responsiveness to

52 dose of allergen needed to provoke an early asthmatic response, reduced the mean maximal fall in FEV

53 malayi can result in development of a severe asthmatic response termed tropical pulmonary eosinophili

54 demonstrated a positive skin test and a dual asthmatic response to allergen inhalation challenge.

55 Th2 and mast cells are participants in the asthmatic response to allergens, and both cell types pro

56 Clinical experiments demonstrate that the asthmatic response to an aeroallergen can be enhanced by

57 However, asthmatic response to corticosteroids also varies widely

58 HR1 have pharmacogenetic effects influencing asthmatic response to corticosteroids, provide a rationa

59 treatment greatly reduces the severity of an asthmatic response to several types of bronchoconstricto

60 is sufficient to mediate key features of the asthmatic responses to IL-13 in murine models.

61 tenuated the early (0-2 h) and late (4-10 h) asthmatic responses to inhaled allergen compared with pl

62 Asthmatic responses were found to involve sequential ind

63 reactive oxygen species during the immediate asthmatic response, whereas nitrosylation during the lat

64 The early asthmatic response with SB010 was attenuated by 11% as m

65 heep effectively antagonized antigen-induced asthmatic responses, with 70-75% blockade of the early r